MPLTMapLight Therapeutics Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combin…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 AstraZeneca scores in lung cancer; Sandoz inks a China deal A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug. | ||
MapLight Therapeutics Launching $150 Million Private Placement Financing MapLight Therapeutics (MPLT) said Thursday it has signed an agreement with investors to sell securit | MMT Newswires | |
 MapLight CEO on what investors missed in the biotech’s schizophrenia data Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data." | ||
 MapLight Therapeutics stock crashes on Phase II schizophrenia data MapLight said the twice-daily dose met the primary endpoint of the schizophrenia trial, but the daily dose did not. | ||
 MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose MapLight announced topline findings from its mid-stage ZEPHYR trial of ML-007C-MA, an oral medicine tested in about 307 adults hospitalized for a sudden worsening of schizophrenia symptoms, on Monday. | ||
Top Midday Decliners MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML | MMT Newswires | |
 Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint Maplight Therapeutics (NASDAQ:MPLT) reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant improvement in Positive and Negative Syndrome Scale, or PANSS, total scores versus placebo at five w | ||
 Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56? MapLight Therapeutics (MPLT) has drawn fresh attention after recent trading left the stock at $36.56, with gains over the past month and past three months contrasting with a mixed shorter term performance. See our latest analysis for MapLight Therapeutics. Looking beyond the latest move, MapLight Therapeutics has shown strong momentum, with a year to date share price return of 118.01% and solid gains over the past quarter and month, despite a softer 7 day share price return. If MapLight... | ||
Sector Update: Healthcare Stocks Rise Late Afternoon Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the | MMT Newswires | |
 Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls | TThe Fly | |
IInsider Monkey | ||